BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

921 related articles for article (PubMed ID: 17353770)

  • 1. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure.
    Maurer MS; Raina A; Hesdorffer C; Bijou R; Colombo P; Deng M; Drusin R; Haythe J; Horn E; Lee SH; Marboe C; Naka Y; Schulman L; Scully B; Shapiro P; Prager K; Radhakrishnan J; Restaino S; Mancini D
    Transplantation; 2007 Mar; 83(5):539-45. PubMed ID: 17353770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis.
    Sack FU; Kristen A; Goldschmidt H; Schnabel PA; Dengler T; Koch A; Karck M
    Eur J Cardiothorac Surg; 2008 Feb; 33(2):257-62. PubMed ID: 18096396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular assist device destination therapy versus extended criteria cardiac transplant.
    Daneshmand MA; Rajagopal K; Lima B; Khorram N; Blue LJ; Lodge AJ; Hernandez AF; Rogers JG; Milano CA
    Ann Thorac Surg; 2010 Apr; 89(4):1205-9; discussion 1210. PubMed ID: 20338335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with long-term survival following cardiac transplantation.
    Sareyyüpoğlu B; Kirali K; Göksedef D; Rabuş MB; Tuncer A; Erentuğ V; Mansuroğlu D; Yakut C
    Anadolu Kardiyol Derg; 2008 Oct; 8(5):360-6. PubMed ID: 18849228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restrictive criteria for heart transplantation candidacy maximize survival of patients with advanced heart failure.
    Frigerio M; Gronda EG; Mangiavacchi M; Andreuzzi B; Colombo T; De Vita C; Oliva F; Quaini E; Pellegrini A
    J Heart Lung Transplant; 1997 Feb; 16(2):160-8. PubMed ID: 9059927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart transplantation in patients with amyloidosis: single-center experience.
    Alloni A; Pellegrini C; Ragni T; Goggi C; D'Armini AM; Rinaldi M; Viganò M
    Transplant Proc; 2004 Apr; 36(3):643-4. PubMed ID: 15110619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
    Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK
    Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
    Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
    Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
    Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey.
    Hosenpud JD; DeMarco T; Frazier OH; Griffith BP; Uretsky BF; Menkis AH; O'Connell JB; Olivari MT; Valantine HA
    Circulation; 1991 Nov; 84(5 Suppl):III338-43. PubMed ID: 1934428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
    Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
    J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of donor-recipient sex matching on survival after orthotopic heart transplantation: analysis of 18 000 transplants in the modern era.
    Weiss ES; Allen JG; Patel ND; Russell SD; Baumgartner WA; Shah AS; Conte JV
    Circ Heart Fail; 2009 Sep; 2(5):401-8. PubMed ID: 19808369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternate waiting list strategies for heart transplantation maximize donor organ utilization.
    Chen JM; Russo MJ; Hammond KM; Mancini DM; Kherani AR; Fal JM; Mazzeo PA; Pinney SP; Edwards NM; Naka Y
    Ann Thorac Surg; 2005 Jul; 80(1):224-8. PubMed ID: 15975371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in patients older than 60 years of age undergoing orthotopic heart transplantation: an analysis of the UNOS database.
    Weiss ES; Nwakanma LU; Patel ND; Yuh DD
    J Heart Lung Transplant; 2008 Feb; 27(2):184-91. PubMed ID: 18267225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible pulmonary hypertension in heart transplant candidates: to transplant or not to transplant.
    Klotz S; Wenzelburger F; Stypmann J; Welp H; Drees G; Schmid C; Scheld HH
    Ann Thorac Surg; 2006 Nov; 82(5):1770-3. PubMed ID: 17062245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orthotopic heart transplantation with donors greater than or equal to 60 years of age: a single-center experience.
    Bruschi G; Colombo T; Oliva F; Morici N; Botta L; Cannata A; Frigerio M; Martinelli L
    Eur J Cardiothorac Surg; 2011 Jul; 40(1):e55-61. PubMed ID: 21450480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey.
    Hosenpud JD; Uretsky BF; Griffith BP; O'Connell JB; Olivari MT; Valantine HA
    J Heart Transplant; 1990; 9(4):346-50. PubMed ID: 2398427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac retransplantation: is it justified in times of critical donor organ shortage? Long-term single-center experience.
    Goerler H; Simon A; Gohrbandt B; Hagl C; Oppelt P; Haverich A; Strueber M
    Eur J Cardiothorac Surg; 2008 Dec; 34(6):1185-90. PubMed ID: 18693029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projected survival benefit as criterion for listing and organ allocation in heart transplantation.
    Krakauer H; Lin MJ; Bailey RC
    J Heart Lung Transplant; 2005 Jun; 24(6):680-9. PubMed ID: 15949727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.